Nemluvio (Nemolizumab)

Nemolizumab is a monoclonal antibody that binds to the interleukin‑31 receptor A on skin and nerve cells. By blocking IL‑31 signaling, it reduces the neuronal transmission of itch and dampens inflammatory pathways that contribute to skin lesions.

The dosing regimen for Nemluvio is determined by the prescribing physician based on the patient’s clinical condition, weight, and response to therapy. Specific dose amounts and intervals are outlined in the product’s prescribing information and should not be altered without medical guidance.

Safety data for Nemluvio in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Nemluvio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Nemluvio belongs to the class of IL‑31 receptor antagonists, offering a targeted approach to itch control that differs from traditional systemic immunosuppressants or broad‑acting biologics such as dupilumab. Its specific mechanism may provide faster itch relief for patients who have not responded to other options.

Nemluvio must be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If refrigeration is unavailable for a short period, follow the manufacturer’s guidance on temperature excursions.

Nemluvio is given by subcutaneous injection, typically in a clinical setting. A healthcare professional prepares the dose according to the prescribing information and administers it into the subcutaneous tissue of the abdomen, thigh, or upper arm.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, and serious infections that may require hospitalization. Patients should be monitored for signs of infection, allergic response, and any unexpected systemic symptoms throughout treatment.

Nemluvio is contraindicated in individuals with known hypersensitivity to nemolizumab or any excipients in the formulation. It should also be avoided in patients receiving live vaccines or those with uncontrolled serious infections until the infection is resolved.